High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018

Erdos J, Fischer S
Record ID 32018000317
English
Authors' objectives: Prostate cancer is one of the most common cancer types in men in Europe. We reviewed current evidence on efficacy and safety of high-intensity focused ultrasound (HIFU) as primary or salvage therapy compared to radiotherapy, active surveillance, watchful waiting, and radical prostatectomy in the treatment of low and intermediate-risk localised or locally recurrent prostate cancer.
Authors' recommendations: The current evidence is insufficient to demonstrate the efficacy and safety of both primary and salvage HIFU compared to other interventions. On the basis of the limited evidence, the inclusion in the Austrian BMG catalogue of procedures is currently not recommended.
Authors' methods: To assess efficacy, one controlled study was evaluated that compared primary HIFU with brachytherapy (a type of radiotherapy) in the treatment of localised prostate cancer. No other controlled trials comparing primary or salvage HIFU with other treatment modalities could be identified. To assess safety, in addition to the controlled study, five prospective case series were evaluated.
Details
Project Status: Completed
URL for project: https://aihta.at/page/bewertung-medizinischer-einzelleistungen-mel-2018/en
Year Published: 2018
URL for published report: http://eprints.aihta.at/1167/1/DSD_37_Update2018.pdf
URL for additional information: http://eprints.aihta.at/1167/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • High-Intensity Focused Ultrasound Ablation
  • Therapeutics
  • Prostatic Neoplasms
  • Minimally Invasive Surgical Procedures
  • Male
  • Ultrasound, High-Intensity Focused, Transrectal
Keywords
  • Prostate cancer
  • high-intensity focused ultrasound
  • ablation therapy
  • non-invasive surgery
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.